Chimerix (NASDAQ:CMRX) Earns Outperform Rating from Wedbush

Chimerix (NASDAQ:CMRX – Get Free Report)‘s stock had its “outperform” rating restated by equities researchers at Wedbush in a research note issued to investors on Tuesday,RTT News reports. They currently have a $7.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $6.00. Wedbush’s price objective would suggest a potential […]